Clinical Trial Update: Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating adbelimumab plus chemotherapy and apatinib for resectable esophageal squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Adbelimumab
• Apatinib (apatinib)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Esophageal Squamous Cell Carcinoma, Neoadjuvant Treatment | Phase 2 | Status: RECRUITING